Literature DB >> 31092497

Primary progressive multiple sclerosis to be treated with ocrelizumab: a mistaken case of cobalamin deficiency.

Sydney Feldman1, Salman Aljarallah1,2, Shiv Saidha1.   

Abstract

Cobalamin (vitamin B12) deficiency often manifests with neurologic symptoms and may rarely mimic multiple sclerosis (MS) among other neurological disorders. However, MRI changes associated with cobalamin deficiency are typically spinal predominant and distinct from MS-related changes. We report a case of a patient with cobalamin deficiency who was recommended by her primary neurologist to commence treatment with ocrelizumab, a potent anti-CD20 B-cell depleting monoclonal antibody, after being diagnosed with primary progressive MS. However, cervical spine MRI demonstrated changes classical of cobalamin deficiency including 'inverted V sign' signal hyperintensity and following parenteral cobalamin supplementation her neurological symptoms quickly and dramatically improved. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  multiple sclerosis; vitamins and supplements

Mesh:

Substances:

Year:  2019        PMID: 31092497      PMCID: PMC6536163          DOI: 10.1136/bcr-2018-229080

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Neurological picture. Nitrous oxide-induced myelopathy with inverted V-sign on spinal MRI.

Authors:  Elias S Sotirchos; Shiv Saidha; Daniel Becker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-08       Impact factor: 10.154

2.  "Inverted V sign" in Sub-Acute Combined Degeneration of Cord.

Authors:  Ramakrishna Narra; Adinarayana Mandapalli; Naganarasimharaju Jukuri; Pradeep Guddanti
Journal:  J Clin Diagn Res       Date:  2015-05-01

3.  Neurologic disease and vitamin B12 deficiency.

Authors:  James Svenson
Journal:  Am J Emerg Med       Date:  2007-10       Impact factor: 2.469

4.  Inverted V sign in hydromyelia with Chiari type 1 malformation.

Authors:  Hung Youl Seok; Mi-Yeon Eun; Hyun Woo Yang
Journal:  Acta Neurol Belg       Date:  2012-07-24       Impact factor: 2.396

Review 5.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

6.  Vitamin B12 Deficiency: Recognition and Management.

Authors:  Robert C Langan; Andrew J Goodbred
Journal:  Am Fam Physician       Date:  2017-09-15       Impact factor: 3.292

7.  Imaging features of copper deficiency myelopathy: a study of 25 cases.

Authors:  Neeraj Kumar; J Eric Ahlskog; Christopher J Klein; John D Port
Journal:  Neuroradiology       Date:  2005-10-28       Impact factor: 2.804

Review 8.  Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials.

Authors:  Christopher C Butler; Josep Vidal-Alaball; Rebecca Cannings-John; Andrew McCaddon; Kerenza Hood; Alexandra Papaioannou; Ian Mcdowell; Andrew Goringe
Journal:  Fam Pract       Date:  2006-04-03       Impact factor: 2.267

Review 9.  Primary-progressive multiple sclerosis.

Authors:  David H Miller; Siobhan M Leary
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

Review 10.  Cobalamin deficiency: clinical picture and radiological findings.

Authors:  Chiara Briani; Chiara Dalla Torre; Valentina Citton; Renzo Manara; Sara Pompanin; Gianni Binotto; Fausto Adami
Journal:  Nutrients       Date:  2013-11-15       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.